Final overall survival for the phase III KN177 study: Pembrolizumab versus chemotherapy in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC)

Oral Abstract Session
Presenter: Thierry Andre, MD
Abstract Number: 3500
Presented: June 7, 2021
Track: Gastrointestinal Cancers
Disclosures: View Disclosures
© 2022 American Society of Clinical Oncology (ASCO®). All Rights Reserved.
Share:
Share on facebook
Share on twitter
Share on linkedin

Other Gastrointestinal Cancers Content

Expert Interview

Gastrointestinal Cancer – Expert Insights

Dr Parikh discusses her ASCO21 highlights for gastrointestinal cancer, including results from the pivotal KEYNOTE-177 study of pembrolizumab versus chemotherapy in MSI-H/dMMR metastatic colorectal cancer (mCRC) (abstract 3500) and the results from DESTINY-CRC01, the phase II trial evaluating trastuzumab derustecan in patients with HER2-expressing advanced colorectal cancer (abstract 3505). She also discusses the CHRONOS trial- a phase II study of anti-EGFR rechallenge therapy with panitumumab in mCRC (abstract 3506).
Interviewee: Aparna Raj Parikh, MD
Interview Date: June 14, 2021
Expert Interview

Gastrointestinal Cancer – Expert Insights

Dr Chau takes us through his ASCO21 highlights in upper tract gastrointestinal cancer, including the ESCORT-1st (abstract 4000), CheckMate 648 (abstract LBA4001), and CheckMate 649 (abstract 4002) trials in the advanced setting, and the Neo-AEGIS (abstract 4004) and CheckMate 577 (abstract 4003) trials in patients with localized disease.
Interviewee: Ian Chau, MD
Interview Date: June 10, 2021
Oral Abstract Session

Trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC): Final results from a phase 2, multicenter, open-label study (DESTINY-CRC01)

Presenter: Takayuki Yoshino, MD, PhD
Presentation Date: June 7, 2021
Abstract Number: 3505
Expert Interview

Gastrointestinal Cancer – Expert Insights

Dr Kelly discusses the expanded efficacy, safety and quality of life (QOL) findings of CheckMate 577- an efficacy and safety analyses of adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer following neoadjuvant CRT (abstract 4003). He also highlights phase III results from the CheckMate 648 study of nivolumab plus chemotherapy and nivolumab plus ipilimumab as 1L treatment for advanced esophageal cancer (abstract LBA4001), and shares his insights about the findings from the phase III ESCORT-1st study which evaluated the efficacy and safety of camrelizumab plus chemotherapy versus chemotherapy in patients with untreated advanced or metastatic esophagaeal squamous cell carcinoma (ESCC) (abstract 4000); as well as topline results from CheckMate 649 (abstract 4066), Keynote 590 (abstract 4049), and Keynote 811 (abstract 4013).
Interviewee: Ronan Joseph Kelly, MBA, MD
Interview Date: June 9, 2021
Oral Abstract Session

Phase II study of anti-EGFR rechallenge therapy with panitumumab driven by circulating tumor DNA molecular selection in metastatic colorectal cancer: The CHRONOS trial

Presenter: Andrea Sartore-Bianchi, MD
Presentation Date: June 7, 2021
Abstract Number: 3506
Oral Abstract Session

ESCORT-1st: A randomized, double-blind, placebo-controlled, phase 3 trial of camrelizumab plus chemotherapy versus chemotherapy in patients with untreated advanced or metastatic esophageal squamous cell carcinoma (ESCC)

Presenter: Rui-hua Xu, MD, PhD
Presentation Date: June 5, 2021
Abstract Number: 4000
Oral Abstract Session

First-line (1L) nivolumab (NIVO) plus chemotherapy (chemo) versus chemo in advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): Expanded efficacy and safety data from CheckMate 649

Presenter: Markus H. Moehler, MD, PhD
Presentation Date: June 5, 2021
Abstract Number: 4002
Oral Abstract Session

Adjuvant nivolumab (NIVO) in resected esophageal or gastroesophageal junction cancer (EC/GEJC) following neoadjuvant chemoradiotherapy (CRT): Expanded efficacy and safety analyses from CheckMate 577

Presenter: Ronan Joseph Kelly, MBA, MD
Presentation Date: June 5, 2021
Abstract Number: 4003
Oral Abstract Session

Neo-AEGIS (Neoadjuvant trial in Adenocarcinoma of the Esophagus and Esophago-Gastric Junction International Study): Preliminary results of phase III RCT of CROSS versus perioperative chemotherapy (Modified MAGIC or FLOT protocol). (NCT01726452)

Presenter: John V. Reynolds, BCh, FRCS, MA, MB, MCh
Presentation Date: June 5, 2021
Abstract Number: 4004
Oral Abstract Session

Nivolumab (NIVO) plus ipilimumab (IPI) or NIVO plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): First results of the CheckMate 648 study

Presenter: Ian Chau, MD
Presentation Date: June 5, 2021
Abstract Number: LBA4001
We'd love your feedback!
We'd love your feedback!

Welcome to ASCO Direct™

2021 Annual Meeting Highlights

Expert insights into key ASCO21 data that will impact clinical practice and patient care plus complimentary access to 50 official ASCO video presentations and downloadable slides, picked by our Experts.

ASCO Direct is an officially licensed program of the American Society of Clinical Oncology® (ASCO®)

This program is supported by Bristol Myers Squibb and brought to you by Springer Healthcare